Live Science11d
FDA approves ketamine-like nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Hosted on MSN21d
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...
Hosted on MSN18d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive ...
Northcountrypublicradio.org21d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has expanded ...
Medindia14d
FDA Approves Esketamine Nasal Spray for Resistant Depression
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The American Journal of Managed Care22d
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...
Popular Science21d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Inquirer on MSN7d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
Medscape19d
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...
MedPage Today22d
FDA Expands Approval of Esketamine for Depression
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who ...